- Home
- PKBK vs SGMT Comparison
PKBK vs SGMT Comparison
Compare PKBK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PKBK | SGMT |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.0M | 164.6M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PKBK | SGMT |
|---|---|---|
| Price | $27.14 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 78.4K | ★ 352.1K |
| Earning Date | 04-23-2026 | 06-10-2026 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | ★ 39.21 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,523.58 |
| P/E Ratio | $8.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.94 | $1.73 |
| 52 Week High | $29.50 | $11.41 |
Technical Indicators
Market Signals| Indicator | PKBK | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 41.75 |
| Support Level | $26.56 | $4.97 |
| Resistance Level | $28.22 | $6.49 |
| Average True Range (ATR) | 0.85 | 0.34 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 18.99 | 7.02 |
Price Performance
Historical ComparisonAbout PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.